[Secondary hyperlipoproteinemia: It is not always as it seems].
Waldmann-Roth E, Parhofer KG.
MMW Fortschr Med. 2025 Apr;167(6):56-59. doi: 10.1007/s15006-025-4776-z.
Hypertriglyceridaemia: an update.
Wierzbicki AS, Kim EJ, Esan O, Ramachandran R.
J Clin Pathol. 2022 Dec;75(12):798-806. doi: 10.1136/jclinpath-2021-207719. Epub 2022 Jun 16.
Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).
Grützmacher P, Öhm B, Szymczak S, Dorbath C, Brzoska M, Kleinert C.
Clin Res Cardiol Suppl. 2017 Mar;12(Suppl 1):22-26. doi: 10.1007/s11789-017-0090-3.
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, Soran H, Prohaska TA, Xia S, Ginsberg HN, Witztum JL, Tsimikas S; Balance Investigators.
N Engl J Med. 2024 May 16;390(19):1781-1792. doi: 10.1056/NEJMoa2400201. Epub 2024 Apr 7.
Severe hypertriglyceridemia: Existing and emerging therapies.
Malick WA, Do R, Rosenson RS.
Pharmacol Ther. 2023 Nov;251:108544. doi: 10.1016/j.pharmthera.2023.108544. Epub 2023 Oct 15.
Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.
Falko JM.
Endocr Pract. 2018 Aug;24(8):756-763. doi: 10.4158/EP-2018-0157.
Lipoprotein(a) as a cardiovascular risk factor: current status.
Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel.
Eur Heart J. 2010 Dec;31(23):2844-53. doi: 10.1093/eurheartj/ehq386. Epub 2010 Oct 21.
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4.
Nurmohamed NS, Navar AM, Kastelein JJP.
J Am Coll Cardiol. 2021 Mar 30;77(12):1564-1575. doi: 10.1016/j.jacc.2020.11.079.
Cholesterol-Lowering Agents.
Hadjiphilippou S, Ray KK.
Circ Res. 2019 Feb;124(3):354-363. doi: 10.1161/CIRCRESAHA.118.313245.
Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
Santos RD, Wiegman A, Caprio S, Cariou B, Averna M, Poulouin Y, Scemama M, Manvelian G, Garon G, Daniels S.
JAMA Pediatr. 2024 Mar 1;178(3):283-293. doi: 10.1001/jamapediatrics.2023.6477.
